Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05558345 · ClinicalTrials.gov registry record · NA
Expression of Stress Markers During Meth Treatment (EXPRESS+)
A NA study of HIV and Substance-Related Disorders, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05558345: Recruiting NA study of HIV and Substance-Related Disorders, sponsored by University of California, Los Angeles.
NCT05558345 is a NA study of HIV and Substance-Related Disorders that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 55 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05558345, a NA study of HIV and Substance-Related Disorders, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.
Conditions Studied
Interventions
- BEHAVIORAL Contingency Management
Study Locations (1)
California
- UCLA Vine Street Clinic - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What NCT05558345 shows while recruiting
NCT05558345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Contingency Management is the first listed.
NCT05558345 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05558345 about?
NCT05558345 is a clinical study titled "Expression of Stress Markers During Meth Treatment (EXPRESS+)". This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use diso...
What is the current status of trial NCT05558345?
This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2022-09-01. Estimated completion is 2026-03-31.
What conditions does trial NCT05558345 study?
This clinical trial studies the following conditions: HIV, Substance-Related Disorders.
What interventions are being tested in trial NCT05558345?
The interventions under investigation include: Contingency Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT05558345?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05558345 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05558345's enrollment target sits among peer trials
55 209th of 303 higher than 92 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Assessing Peer Support for Physical Activity in Women With HIV and Hypertension
RECRUITING · NA
-
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI